This licence authorises manufacture by the licence holder named; if the business should change hands, the company or person taking over the business will have to obtain a new licence before commencing the manufacturing of medical devices.
This licence is subject to the limitations specified in the licence and to the statutory provisions contained in the Regulations to the Act.
Objective: To estimate whether the topical debriding agent, Debrichem, could potentially afford the UK’s National Health Service (NHS) a cost-effective intervention for the management of
All testing was performed in triplicate and testing was completed twice, separated by 2 weeks apart. This was to ensure reproducibility (Parker et al., 2018).
“If biofilms keep chronic wounds from healing, then Debrichem® is the solution” It is with great pride and anticipation that Debx Africa (Pty) Ltd are
The licence holder and the persons described and named in Annexure 1 shall at all times ensure that all medical devices distributed, irrespective of its
Within one minute of topical application of a red gel intends to facilitate the removal of unhealthy tissue. The semi fluid substance containing an acid
